PCSK9 and familial hyperaldosteronism: Our findings indicate the favorable role of this novel lipid-lowering strategy on lipid and inflammatory profiles and PWV; however, a randomized controlled trial is required to evaluate the effect of PCSK9-i therapy on these pathological aspects in FH subjects.